抗血小板聚集药物的机制研究进展

被引：11

作者：

王晓锋 ^{[1
,2
,3
]}

陈乃宏 ^{[2
]}

王文 ^{[3
]}

机构：

[1] 天津中医药大学

[2] 中国医学科学院协和药物所

[3] 首都医科大学宣武医院药物研究室

来源：

中国康复理论与实践 | 2010年 / 10期

基金：

北京市自然科学基金;

关键词：

抗血小板聚集药物; 机制; 综述;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

通过文献综述,发现抗血小板聚集药物在心血管疾病中有良好应用,但其出血不良反应仍存在,一些新药机制不明确。因此,抗血小板聚集的机制研究还需加快。一种新型的抗血小板聚集药物终将诞生,如EP3受体抑制剂,为新抗血小板聚集药物的研究提供思路。

引用

页码：954 / 957

页数：4

共 11 条

[1] 哒嗪酮类化合物的合成及其抗血小板聚集活性 [J].

章杰兵 ;

柴晓云 ;

俞世冲 ;

古卓良 ;

周国华 .

第二军医大学学报, 2009, 30 (07) :821-824

[2] 抗血小板药物研究进展 [J].

郭晖 ;

刘媛 ;

胡玉龙 .

中国药物与临床, 2007, (09) :694-695

[3] 规范应用阿司匹林治疗缺血性脑血管病的专家共识 [J].

中华内科杂志, 2006, (01) :81-82

[4]

Effect of the carthamins yellow from Carthamus tinctorius L. on hemorheological disorders of blood stasis in rats[J] . Hai-Xia Li,Shu-Yan Han,Xian-Wei Wang,Xu Ma,Ke Zhang,Li Wang,Zhi-Zhong Ma,Peng-Fei Tu.Food and Chemical Toxicology . 2009 (8)

[5]

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease[J] . C. Steven Ernest,David S. Small,Shashank Rohatagi,Daniel E. Salazar,Lars Wallentin,Kenneth J. Winters,Rebecca E. Wrishko.Journal of Pharmacokinetics and Pharmacodynamics . 2009 (6)

[6]

Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel （3T/2R）. Rationale for the Study and Protocol Design[J] . Marco Valgimigli,Gianluca Campo,Nicoletta Cesare,Pascal Vranckx,Martial Hamon,Dominick J. Angiolillo,Manel Sabatè,Fabrizio Ferrari,Alessandro Furgieri,Carlo Tumscitz,Alessandra Repetto,Salvatore Colangelo,Emanuele Meliga,Moh’d Kubbajeh,Giovanni Parrinello,Gianfranco Percoco,Roberto Ferrari.Cardiovascular Drugs and Therapy . 2008 (

[7] The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures [J].

Velat, Gregory J. ;

Burry, Matthew V. ;

Eskioglu, Eric ;

Dettorre, Rebecca R. ;

Firment, Christopher S. ;

Mericle, Robert A. .

SURGICAL NEUROLOGY, 2006, 65 (04) :352-359

[8]

Initial experience with an intravenous P2Y 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial[J] . Adam B. Greenbaum,Cindy L. Grines,John A. Bittl,Richard C. Becker,Dean J. Kereiakes,Ian C. Gilchrist,Jane Clegg,Jill E. Stankowski,Donna R. Grogan,Robert A. Harrington,Hakan Emanuelsson,W. Douglas Weaver.American Heart Journal . 2006 (3)

[9]

FK419, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, Ameliorates Brain Infarction Associated with Thrombotic Focal Cerebral Ischemia in Monkeys: Comparison with Tissue Plasminogen Activator[J] . Masashi Maeda,Akira Moriguchi,Kayoko Mihara,Toshiaki Aoki,Hiroyuki Takamatsu,Nobuya Matsuoka,Seitaro Mutoh,Toshio Goto.Journal of Cerebral Blood Flow ＆ Metabolism . 2005 (1)

[10]

Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond[J] . Shaker A. Mousa.Drug Discovery Today . 1999 (12)

← 1 2 →